Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years

Next Previous
Search
Trial Profile

A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus 6/11 vaccine recombinant bivalent Xiamen (Primary) ; Recombinant hepatitis E vaccine (Hecolin)
  • Indications Condylomata acuminata
  • Focus Pharmacodynamics

    • Most Recent Events

    • 13 Jun 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
    • 13 Jun 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
    • 10 Feb 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top